Valeant Pharmaceuticals Intl Inc  

(Public, NYSE:VRX)   Watch this stock  
Find more results for NYSE:BVF
25.33
-1.09 (-4.13%)
Real-time:   11:50AM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 25.32 - 26.45
52 week 18.55 - 182.64
Open 26.44
Vol / Avg. 5.36M/23.40M
Mkt cap 8.70B
P/E     -
Div/yield     -
EPS -2.86
Shares 341.19M
Beta 0.07
Inst. own 58%
Oct 17, 2016
Q3 2016 Valeant Pharmaceuticals International Inc Earnings Release (Estimated) Add to calendar
Sep 13, 2016
Valeant Pharmaceuticals International Inc at Morgan Stanley Global Healthcare Conference - Webcast
Sep 7, 2016
Valeant Pharmaceuticals International Inc at Wells Fargo Securities Healthcare Conference
Aug 9, 2016
Q2 2016 Valeant Pharmaceuticals International Inc Earnings Call
Aug 9, 2016
Pharming Announces Acquisition of all North American Commercialisation Rights to RUCONEST´┐Ż From Valeant Pharmaceuticals International Inc Conference Call
Aug 9, 2016
Q2 2016 Valeant Pharmaceuticals International Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -12.56% -2.75%
Operating margin 3.33% 14.43%
EBITD margin - 45.71%
Return on average assets -2.52% -0.76%
Return on average equity -22.14% -5.21%
Employees 22,000 -
CDP Score - -

Address

2150 Saint-Elzear Blvd W
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, CeraVe, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Officers and directors

Joseph C. Papa Chairman of the Board, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
Paul S. Herendeen Chief Financial Officer, Executive Vice President - Finance
Age: 60
Bio & Compensation  - Reuters
Pavel Mirovsky President, General Manager, Europe
Age: 65
Bio & Compensation  - Reuters
Christina Ackermann Executive Vice President, General Counsel
Bio & Compensation  - Reuters
Thomas Appio Executive Vice President, President - Asia Pacific
Bio & Compensation  - Reuters
Ari S. Kellen Executive Vice President, Company Group Chairman
Age: 52
Bio & Compensation  - Reuters
Robert L. Rosiello Executive Vice President - Corporate Development and Strategy
Age: 58
Bio & Compensation  - Reuters
Anne C. Whitaker Executive Vice President
Age: 48
Bio & Compensation  - Reuters
Sherri Wilkin Chief Creative Officer
Bio & Compensation  - Reuters
Thomas W. Ross Sr. Lead Independent Director
Age: 65
Bio & Compensation  - Reuters